Get the Daily Brief
Latest Biotech News
Oral GLP-1 pill rivals injectables: Structure posts 44‑week, phase‑2 win
Structure Therapeutics reported Phase 2 results showing its oral GLP‑1 candidate aleniglipron produced substantial, sustained weight loss in a 44‑week study. The company said participants on...
Federal judge freezes ACIP overhaul: vaccine schedule, appointments stayed
A federal judge issued a stay pausing major elements of Health and Human Services Secretary Robert F. Kennedy Jr.'s overhaul of the Advisory Committee on Immunization Practices (ACIP) and the...
CytomX data and Astellas exit: masked ADC story tightens
CytomX reported encouraging Phase 1 expansion data for its masked, conditionally activated antibody‑drug conjugate Varseta‑M in late‑line metastatic colorectal cancer, showing response rates up to...
Standardizing genomic pipeline: metapipeline‑DNA goes cloud‑scale
Researchers from Sanford Burnham Prebys and UCLA released metapipeline‑DNA, an automated, extensible Nextflow pipeline for germline and somatic DNA sequencing analysis designed for cloud and HPC...
ARPA‑H funds digital gene‑therapy manufacturing: $9.3M award to BioCurie
ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven, data‑centric platform for scalable gene‑therapy manufacturing. The program seeks to replace trial‑and‑error process development...
LNP chemistry advances: redesigned lipids and media tweaks raise delivery bar
Two separate preclinical efforts reported improvements to lipid nanoparticle (LNP) performance for mRNA and gene therapies. University of Pennsylvania researchers showed crosslinked ionizable...
PerturbAI publishes 8M‑cell in‑vivo CRISPR atlas: public resource for causal genomics
PerturbAI emerged from stealth with a public in‑vivo Perturb‑seq atlas mapping gene function across 8 million mouse brain cells. The San Francisco startup, backed by a pre‑seed round and...
Big pharma builds an AI factory: Roche, Nvidia expand compute for drug R&D
Roche confirmed plans to expand its partnership with Nvidia to build a large AI 'factory' aimed at accelerating drug discovery and diagnostic development, following a broader pharma push to secure...
In vivo base editing reverses neurodevelopmental disorder – preclinical milestone
Researchers published results showing in‑vivo base editing corrected a genetic lesion and reversed disease phenotypes in a neurodevelopmental disorder model. The work, reported in Nature...
New renal biotech R1 raises $77.5M to advance oral hyperphosphatemia drug
R1 Therapeutics launched with an oversubscribed $77.5 million Series A to advance AP‑306, an oral pan‑phosphate transporter inhibitor for hyperphosphatemia in chronic kidney disease (CKD). The...
Judge halts overhaul of U.S. childhood vaccine policy — ACIP appointments stayed
A federal judge has temporarily blocked major elements of Health and Human Services Secretary Robert F. Kennedy Jr.’s changes to U.S. childhood immunization policy, staying votes by the...
R1 Therapeutics launches with $77.5M to advance AP306 for dialysis-related hyperphosphatemia
R1 Therapeutics unveiled a $77.5 million Series A to develop AP306 (formerly EOS789), a pan‑phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease patients on...
Structure’s oral GLP‑1 pill posts 44‑week weight loss that rivals injectables
Structure Therapeutics reported 44‑week Phase 2 data showing its oral GLP‑1 agonist aleniglipron produced up to ~16% placebo‑adjusted weight loss, reinforcing the company’s claim of...
CytomX’s masked ADC posts responses in late‑line colorectal cancer — stock rallies
CytomX reported expansion‑cohort data from a Phase 1 study of Varseta‑M, a ‘masked’ conditionally activated antibody‑drug conjugate targeting EpCAM, showing objective response rates of 20–32% at...
Bicycle Therapeutics cuts 30% of workforce after regulatory setback on lead oncology asset
Bicycle Therapeutics announced a 30% workforce reduction and a strategic de‑prioritization of its Padcev challenger following an unexpected regulatory setback that extended the path to approval....
PerturbAI releases largest in‑vivo CRISPR brain atlas — dataset of 8M cells
PerturbAI emerged from stealth and publicly released an in‑vivo Perturb‑seq CRISPR atlas mapping gene function across 8 million mouse brain cells, generated with partners 10x Genomics, NVIDIA and...
Roche inks Nvidia partnership to build a large‑scale pharma 'AI factory'
Roche expanded its AI and compute ambitions by striking a deal with Nvidia to build an ‘AI factory’ intended to accelerate drug discovery and diagnostic development. The initiative follows a...
weMERFISH: whole‑embryo, 3D spatial transcriptomics advances developmental mapping
Researchers at the University of Basel published weMERFISH, an extension of MERFISH that enables three‑dimensional, whole‑embryo spatial transcriptomics over time. The platform detected...
ARPA‑H awards BioCurie up to $9.3M to build AI‑driven gene therapy manufacturing platform
ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑powered digital platform intended to speed and standardize gene therapy process development across viral and non‑viral manufacturing....
Trenchant and Invetech advance fully automated, point‑of‑care CGT AutoCell manufacturing
Trenchant BioSystems and Invetech announced a collaboration to commercialize AutoCell, a fully automated cell and gene therapy (CGT) manufacturing platform that could enable point‑of‑care...